TG Therapeutics, Inc.
NASDAQ:TGTXBiotechnology
+$1.03 today
- Market cap
- $9.99B
- Beta
- 1.68
- P/E (TTM)
- 16.4
- EPS (TTM)
- $3.20
Volume 1.87M
Average 2.15M
TGTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
TG Therapeutics, Inc.NASDAQ: TGTX
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q3 FY2026 stock-based compensation of $24.7M rose 39.7% year over year, behind the +44.6% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 11.4% from the prior quarter. Over 3 fiscal years it compounded at +49.9% a year.
Context
- Stock-based compensation amounted to 10.5% of revenue in FY2025, down 2.4 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +39.7% toward the trailing-twelve-month pace of +44.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 64.67M USD
- Year-over-year change
- +52.0%
- 4-year CAGR
- +1.4%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 64.67M | +52.0% |
| FY2024 | 2024-12-31 | 42.54M | +12.1% |
| FY2023 | 2023-12-31 | 37.93M | +97.7% |
| FY2022 | 2022-12-31 | 19.19M | -68.7% |
| FY2021 | 2021-12-31 | 61.27M | — |
Stock-Based Compensation vs competitors
How TGTX compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +44.6% is the 2nd highest of 7, against a peer median of +9.1%.
- Stock-based compensation amounts to 9.8% of revenue for TGTX, versus a peer median of 37.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $88.18M USD | +44.6% | +49.9% | 9.8% | |
| LTM Jun 2026 | $71M USD | — | — | 1.7% | |
| LTM Jun 2026 | $39.03M USD | +10.2% | -4.0% | 37.2% | |
| LTM Sep 2026 | $36.81M USD | -0.7% | — | 32869.6% | |
| LTM Mar 2026 | $12.63M USD | +26.4% | -48.5% | 16.0% | |
| LTM Mar 2026 | $12.55M USD | -55.6% | -11.3% | 8.0% | |
| LTM Jun 2024 | $7.27M USD | — | -29.1% | 891.4% | |
| LTM Mar 2026 | $6.73M USD | +88.8% | +25.6% | — | |
| FY2025 | €4.26M EUR | +7.9% | +0.1% | 152.7% | |
| Peer median (excluding TGTX) | — | +9.1% | -7.6% | 37.2% | |
Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (348.1M) | (198.34M) | 12.67M | 23.38M | 447.18M |
| Depreciation & Amortization | 494K | 515K | 423K | 280K | 244K |
| Deferred Income Tax | 517K | 0 | 0 | 0 | (348M) |
| Stock-Based Compensation | 61.27M | 19.19M | 37.93M | 42.54M | 64.67M |
| Change in Working Capital | (12.22M) | (1.65M) | (84.66M) | (109.3M) | (194.54M) |
| Accounts Receivables | (1.39M) | 1.39M | (51.09M) | (78.09M) | (176.44M) |
| Inventory | (15.99M) | 0 | (36.94M) | (66.85M) | (33.45M) |
| Accounts Payables | 15.99M | (11.01M) | 192K | 0 | 55.88M |
| Other Working Capital | (10.83M) | 7.97M | 3.18M | 35.65M | (40.52M) |
| Other Non-Cash Items | 2.4M | 4.11M | 2.22M | 2.58M | 5.67M |
| Operating Cash Flow | (295.63M) | (176.17M) | (31.41M) | (40.52M) | (24.77M) |
| Capital Expenditures | (401K) | (14K) | 0 | (45K) | (214K) |
| Acquisitions (Net) | (69K) | 20M | 0 | 0 | 0 |
| Purchases of Investments | (55.53M) | (107.27M) | (146.88M) | (311.89M) | (223.49M) |
| Sales of Investments | 55.6M | 87.28M | 96.23M | 310.9M | 237.5M |
| Other Investing Activities | 69K | (20M) | 0 | 0 | 0 |
| Investing Cash Flow | (332K) | (20.01M) | (50.65M) | (1.04M) | 13.8M |
| Debt Repayment | 40M | (975K) | 25M | 137.26M | 0 |
| Common Stock Issued | 2.22M | 584K | 46.3M | 0 | 1.51M |
| Common Stock Repurchased | 0 | 0 | 0 | (8.76M) | (91.24M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (800K) | 0 | 1.41M | 25K | 0 |
| Financing Cash Flow | 41.42M | (391K) | 72.71M | 128.53M | (89.73M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (254.55M) | (196.57M) | (9.36M) | 86.97M | (100.7M) |
| Free Cash Flow | (296.04M) | (176.18M) | (31.41M) | (40.56M) | (24.99M) |
TG Therapeutics, Inc.
NASDAQ:TGTX
Intrinsic Alpha fair value
Locked
Current Price
$66.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.